Free Trial
NASDAQ:OCGN

Ocugen Q4 2023 Earnings Report

Ocugen logo
$1.00 0.00 (-0.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.00 0.00 (-0.34%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen EPS Results

Actual EPS
-$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ocugen Revenue Results

Actual Revenue
$6.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ocugen Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, April 16, 2024
Conference Call Time
7:00AM ET

Ocugen Earnings Headlines

REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
Ocugen (NASDAQ:OCGN) Given Buy Rating at Chardan Capital
See More Ocugen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ocugen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocugen and other key companies, straight to your email.

About Ocugen

Ocugen (NASDAQ:OCGN), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

View Ocugen Profile

More Earnings Resources from MarketBeat